BRAF and neoplasm: Although high concordance rates have been described in some studies (Vermaat et al., 2012), others do report heterogeneity in RAS and BRAF mutations ranging from 5% to 32% between the primary tumor and metastatic sites (Artale et al., 2008; He et al., 2016; Italiano et al., 2010; Kim et al., 2012; Vermaat et al., 2012).